Strive Asset Management LLC Decreases Stock Position in Johnson & Johnson $JNJ

Strive Asset Management LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 8.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,139 shares of the company’s stock after selling 358 shares during the period. Strive Asset Management LLC’s holdings in Johnson & Johnson were worth $686,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Integrity Alliance LLC. lifted its holdings in Johnson & Johnson by 239.0% in the 1st quarter. Integrity Alliance LLC. now owns 32,018 shares of the company’s stock valued at $5,310,000 after purchasing an additional 22,572 shares in the last quarter. Ransom Advisory Ltd purchased a new position in Johnson & Johnson in the 1st quarter valued at about $2,023,000. Ilmarinen Mutual Pension Insurance Co lifted its holdings in Johnson & Johnson by 2.8% in the 1st quarter. Ilmarinen Mutual Pension Insurance Co now owns 366,600 shares of the company’s stock valued at $60,797,000 after purchasing an additional 10,000 shares in the last quarter. SageView Advisory Group LLC lifted its holdings in Johnson & Johnson by 23.3% in the 1st quarter. SageView Advisory Group LLC now owns 21,506 shares of the company’s stock valued at $3,567,000 after purchasing an additional 4,061 shares in the last quarter. Finally, Advisory Alpha LLC lifted its holdings in Johnson & Johnson by 16.8% in the 1st quarter. Advisory Alpha LLC now owns 8,431 shares of the company’s stock valued at $1,398,000 after purchasing an additional 1,215 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.6%

NYSE JNJ opened at $177.12 on Wednesday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The company has a 50-day moving average of $169.51 and a 200-day moving average of $161.02. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market cap of $426.57 billion, a P/E ratio of 18.94, a P/E/G ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the firm posted $2.82 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on JNJ shares. Bank of America upped their target price on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Thursday, July 17th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Friday, September 5th. Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Guggenheim reaffirmed a “neutral” rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.